Eczema future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 9: | Line 9: | ||
*More emphasis on [[genetic studies]] will be given in the future to unfold the remaining majority of unexplained [[heritability]] in [[eczema]]. However, the challenge still lies in the economical and computational requirements. | *More emphasis on [[genetic studies]] will be given in the future to unfold the remaining majority of unexplained [[heritability]] in [[eczema]]. However, the challenge still lies in the economical and computational requirements. | ||
* These [[genetic discoveries]] can be applied to the development of new [[drugs]] that can target the [[molecular]] and [[physiological]] [[causes]] of the [[disease]], making an era of "personalized [[medicine]]". <ref name="pmid29217837">{{cite journal| author=Dugger SA, Platt A, Goldstein DB| title=Drug development in the era of precision medicine. | journal=Nat Rev Drug Discov | year= 2018 | volume= 17 | issue= 3 | pages= 183-196 | pmid=29217837 | doi=10.1038/nrd.2017.226 | pmc=6287751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29217837 }} </ref> | * These [[genetic discoveries]] can be applied to the development of new [[drugs]] that can target the [[molecular]] and [[physiological]] [[causes]] of the [[disease]], making an era of "personalized [[medicine]]". <ref name="pmid29217837">{{cite journal| author=Dugger SA, Platt A, Goldstein DB| title=Drug development in the era of precision medicine. | journal=Nat Rev Drug Discov | year= 2018 | volume= 17 | issue= 3 | pages= 183-196 | pmid=29217837 | doi=10.1038/nrd.2017.226 | pmc=6287751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29217837 }} </ref> | ||
* [[Digitalization]] and [[artificial intelligence]] can also be applied to the [[management]] of [[eczema]]. <ref name="pmid33205485">{{cite journal| author=Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M | display-authors=etal| title=ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. | journal=J Eur Acad Dermatol Venereol | year= 2020 | volume= 34 | issue= 12 | pages= 2717-2744 | pmid=33205485 | doi=10.1111/jdv.16892 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33205485 }} </ref> | |||
Revision as of 18:37, 23 May 2022
|
Eczema Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eczema On the Web |
|
American Roentgen Ray Society Images of Eczema |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
More emphasis on genetic studies will be given in the future to unfold the remaining majority of unexplained heritability in eczema. However, the challenge still lies in the economical and computational requirements. [1]
Eczema Future or Investigational Therapies
- More emphasis on genetic studies will be given in the future to unfold the remaining majority of unexplained heritability in eczema. However, the challenge still lies in the economical and computational requirements.
- These genetic discoveries can be applied to the development of new drugs that can target the molecular and physiological causes of the disease, making an era of "personalized medicine". [2]
- Digitalization and artificial intelligence can also be applied to the management of eczema. [3]
References
- ↑ Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S; et al. (2012). "Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect". J Invest Dermatol. 132 (1): 98–104. doi:10.1038/jid.2011.342. PMC 3236450. PMID 22071473.
- ↑ Dugger SA, Platt A, Goldstein DB (2018). "Drug development in the era of precision medicine". Nat Rev Drug Discov. 17 (3): 183–196. doi:10.1038/nrd.2017.226. PMC 6287751. PMID 29217837.
- ↑ Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M; et al. (2020). "ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children". J Eur Acad Dermatol Venereol. 34 (12): 2717–2744. doi:10.1111/jdv.16892. PMID 33205485 Check
|pmid=value (help).